

Fintepla

Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-249-6155**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-866-814-5506**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:		Date: Patient's Date of Birth:	
Physician's Name: Specialty:		NPI#:	
Ph	ysician Office Telephone:	Physician Office Fax:	
Re	quest Initiated For:		
1.	What is the diagnosis? ☐ Seizures associated with Dravet syndrome ☐ Seizures associated with Lennox-Gastaut syndrome ☐ Other		
2.	What is the ICD-10 code?		
	tion A: Preferred Product Is the product being requested for the treatment of	of seizure disorders?	
4.	Trokendi XR. Can the patient's treatment be switten to have the updated form faxed to your office out online via CoverMyMeds at: www.covermyn	plan are clobazam, lamotrigine, rufinamide, topiramate, and teched to a preferred product? If Yes, please call 1-866-814-5506 PR you may complete the PA electronically (ePA). You may sign meds.com/epa/caremark/ or call 1-866-452-5017. No - continue request for non-preferred product	
5.	Is this request for continuation of therapy with the	ne requested product? 🗖 Yes 📮 No If No, skip to #7	
6.	Is the patient currently receiving the requested product through samples or a manufacturer's patient assistance program? If unknown, answer Yes. \square Yes \square No If No, skip to next section.		
7.	Does the patient have a diagnosis of seizures associated with Dravet syndrome? If Yes, skip to next section. \square Yes \square No		
8.	Does the patient have a documented inadequate response to treatment with at least 3 of the preferred product(s) (clobazam, lamotrigine, rufinamide, topiramate, Trokendi XR)? <i>ACTION REQUIRED: Submit supporting documentation. If Yes, skip to next section.</i> \square Yes \square No		
9.		adverse event to at least 3 of the preferred product(s) (clobazam, R)? ACTION REQUIRED: Submit supporting documentation.	
	ction B: All Requests Will Fintepla be taken in combination with phen	termine? □ Yes □ No	

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Fintepla SGM - 7/2023.

11.	Is the request for continuation of therapy with the requested medication? ☐ Yes ☐ No If No, no further questions			
12.	. Has the member achieved and maintained positive clinical response as evidenced by reduction in frequency or duration of seizures compared with seizure activity prior to starting Fintepla? Yes No			
	I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.			
Y	v v z v			
Pre	escriber or Authorized Signature	Date (mm/dd/yy)		

Send completed form to: Case Review Unit CVS Caremark Prior Authorization Fax: 1-866-249-6155

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Fintepla SGM - 7/2023.